Pitavastatin-attenuated cardiac dysfunction in mice with dilated cardiomyopathy via regulation of myocardial calcium handling proteins

1. A. Bielecka-Dabrowa, D. P. Mikhailidis, S. Hannam, W. S. Aronow, J. Rysz and M. Banach, Statins and dilated cardiomyopathy: do we have enough data, Expert Opin. Investig. Drugs 20 (2011) 315-323; DOI: 10.1517/13543784.2011.550570.10.1517/13543784.2011.55057021210757Search in Google Scholar

2. M. Touvron, B. Escoubet, M. Mericskay, A. Angelini, L. Lamotte, M. P. Santini, N. Rosenthal, D. Daegelen, D. Tuil and J. F. Decaux, Locally expressed IGF1 propeptide improves mouse heart function in induced dilated cardiomyopathy by blocking myocardial fibrosis and SRF-dependent CTGF induction, Dis. Model. Mech. 5 (2012) 481-491; DOI: 10.1242/dmm.009456.10.1242/dmm.009456338071122563064Search in Google Scholar

3. L. Werner, V. Deutsch, I. Barshack, H. Miller, G. Keren and J. George, Transfer of endothelial progenitor cells improves myocardial performance in rats with dilated cardiomyopathy induced following experimental myocarditis, J. Mol. Cell. Cardiol. 39 (2005) 691-697; DOI: 10.1016/ j.yjmcc.2005.06.015.10.1016/j.yjmcc.2005.06.01516125196Search in Google Scholar

4. E. Hoshikawa, Y. Matsumura, T. Kubo, M. Okawa, N. Yamasaki, H. Kitaoka, T. Furuno, J. Takata and Y. L. Doi, Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta blockers in patients with idiopathic dilated cardiomyopathy, Am. J. Cardiol. 107 (2011) 1065-1070; DOI: 10.1016/j.amjcard.2010.11.033.10.1016/j.amjcard.2010.11.03321296328Search in Google Scholar

5. W. B. Zhang, Du QJ, H. Li, A. J. Sun, Z. H. Qiu, C. N.Wu, G. Zhao, H. Gong, K. Hu, Y. Z. Zou and J. B. Ge, The therapeutic effect of rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end-stage hypertension in rats, J. Cell. Mol. Med. 16 (2012) 2227-2237; DOI: 10.1111/j.1582-4934.2012.01536.x.10.1111/j.1582-4934.2012.01536.x382299222288611Search in Google Scholar

6. J. J. Goldberger, H. Subacius, A. Schaechter, A. Howard, R. Berger, A. Shalaby, J. Levine and A. H. Kadish, Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy, J. Am. Coll. Cardiol. 48 (2006) 1228-1233; DOI: 10.1016/j.jacc. 2006.05.053.Search in Google Scholar

7. F. Tehrani, R. Morrissey, A. Phan, C. Chien and E. R. Schwarz, Statin therapy in patients with diastolic heart failure, Clin. Cardiol. 33 (2010) E1-E5; DOI: 10.1002/clc.20615.10.1002/clc.20615665329520127896Search in Google Scholar

8. S. K. Thambidorai, A. R. Deshmukh, R. W. Walters, P. D. Turner,M. S.Monaghan, A. N. Mooss, C. B. Hunter, D. J. Esterbrooks and S. M. Mohiuddin, Impact of statin use on heart failure mortality, Int. J. Cardiol. 147 (2011) 438-443; DOI: 10.1016/j.ijcard.2010.08.016.10.1016/j.ijcard.2010.08.01620971517Search in Google Scholar

9. T. Sakamoto, S. Kojima, H. Ogawa, H. Shimomura, K. Kimura, Y. Ogata, N. Sakaino and A. Kitagawa, Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese, Am. J. Cardiol. 97 (2006) 1165-1171; DOI: 10.1016/ j.amjcard.2005.11.031.10.1016/j.amjcard.2005.11.03116616020Search in Google Scholar

10. R. Jarai, C. Kaun, T. W. Weiss, W. S. Speidl, K. Rychli, G. Maurer, K. Huber and J. Wojta, Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1 alpha, tumour necrosis factor-alpha and transforming growth factor-beta, J. Cell. Mol. Med. 13 (2009) 4415-4421; DOI: 10.1111/j.1582-4934.2009.00704.x.10.1111/j.1582-4934.2009.00704.x451505719228263Search in Google Scholar

11. P. E. Lazzerini, P. L. Capecchi and F. Laghi-Pasini, Statins as a new therapeutic perspective in myocarditis and postmyocarditis dilated cardiomyopathy, Cardiovasc. Drugs Ther. 27 (2013) 365-369; DOI: 10.1007/s10557-013-6475-8.10.1007/s10557-013-6475-823832693Search in Google Scholar

12. Y. Kameda, H. Hasegawa, A. Kubota, H. Tadokoro, Y. Kobayashi, I. Komuro and H. Takano, Effects of pitavastatin on pressure overload-induced heart failure in mice, Circ. J. 76 (2012) 1159-1168; DOI: 10.1253/circj.CJ-11-1114.10.1253/circj.CJ-11-1114Search in Google Scholar

13. T. Aoyagi, F. Nakamura, T. Tomaru and T. Toyo-Oka, Beneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failure, Int. Heart J. 49 (2008) 49-58; DOI: 10.1536/ihj.49.49.10.1536/ihj.49.4918360064Search in Google Scholar

14. H. Takano, H. Mizuma, Y. Kuwabara, Y. Sato, S. Shindo, N. Kotooka, D. Fujimatsu, Y. Kobayashi, T. Inoue, K. Node and I. Komuro, Effects of pitavastatin in Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study), Circ. J. 77 (2013) 917-925; DOI: 10.1253/circj.CJ-12-1062.10.1253/circj.CJ-12-106223502990Search in Google Scholar

15. J. Kjekshus, E. Apetrei, V. Barrios, M. Bohm, J. G. Cleland, J. H. Cornel, P. Dunselman, C. Fonseca, A. Goudev, P. Grande, L. Gullestad, A. Hjalmarson, J. Hradec, A. Janosi, G. Kamensky, M. Komajda, J. Korewicki, T. Kuusi, F. Mach, V. Mareev, J. J. McMurray, N. Ranjith, M. Schaufelberger, J. Vanhaecke, D. J. van Veldhuisen, F. Waagstein, H. Wedel and J. Wikstrand, Rosuvastatin in older patients with systolic heart failure, N. Engl. J. Med. 357 (2007) 2248-2261; DOI: 10.1056/NEJMoa0706201.10.1056/NEJMoa070620117984166Search in Google Scholar

16. S. A. Chang, Y. J. Kim, H. W. Lee, D. H. Kim, H. K. Kim, H. J. Chang, D. W. Sohn, B. H. Oh and Y. B. Park, Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy, Hypertension 54 (2009) 591-597; DOI: 10.1161/HYPERTENSIONAHA.109.131243.10.1161/HYPERTENSIONAHA.109.13124319564547Search in Google Scholar

17. K. Krishnamurthy, R. Kanagasabai, L. J. Druhan and G. Ilangovan, Heat shock protein 25-enriched plasma transfusion preconditions the heart against doxorubicin-induced dilated cardiomyopathy in mice, J. Pharmacol. Exp. Ther. 341 (2012) 829-839; DOI: 10.1124/jpet.112.192245.10.1124/jpet.112.192245336288022438470Search in Google Scholar

18. F.N.Gava, E. Zacche, E.M.Ortiz, T. Champion,M. B. Bandarra, R. O. Vasconcelos, J. C. Barbosa and A. A. Camacho, Doxorubicin induced dilated cardiomyopathy in a rabbit model: an update, Res. Vet. Sci. 94 (2013) 115-121; DOI: 10.1016/j.rvsc.2012.07.027.10.1016/j.rvsc.2012.07.02722902286Search in Google Scholar

19. K. Suzuki, B. Murtuza, N. Suzuki, R. T. Smolenski andM. H. Yacoub, Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure, Circulation 104 (2001) 1213-1217; DOI: 10.1161/hc37t1.094929.10.1161/hc37t1.09492911568058Search in Google Scholar

20. M. Sano, T. Minamino, H. Toko, H. Miyauchi, M. Orimo, Y. Qin, H. Akazawa, K. Tateno, Y. Kayama, M. Harada, I. Shimizu, T. Asahara, H. Hamada, S. Tomita, J. D. Molkentin, Y. Zou and I. Komuro, p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload, Nature 446 (2007) 444-448; DOI: 10.1038/nature05602.10.1038/nature0560217334357Search in Google Scholar

21. Y. C. Liao, Y. C. Hsieh, C. Y. Hung, J. L. Huang, C. H. Lin, K. Y.Wang and T. J. Wu, Statin therapy reduces the risk of ventricular arrhythmias, sudden cardiac death, and mortality in heart failure patients: A nationwide population-based cohort study, Int. J. Cardiol. 2013, in press; DOI: 10.1016/j.ijcard.2013.07.036.10.1016/j.ijcard.2013.07.03623890884Search in Google Scholar

22. A. Tidholm, J. Haggstrom and K. Hansson, Effects of dilated cardiomyopathy on the renin- -angiotensin-aldosterone system, atrial natriuretic peptide activity, and thyroid hormone concentrations in dogs, Am. J. Vet. Res. 62 (2001) 961-967; DOI: 10.2460/ajvr.2001.62.961.10.2460/ajvr.2001.62.96111400857Search in Google Scholar

23. X. Y. Tian, W. T. Wong, A. Xu, Z. Y. Chen, Y. Lu, L. M. Liu, V. W. Lee, C.W. Lau, X. Yao and Y. Huang, Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress, Br. J. Pharmacol. 164 (2011) 598-606; DOI: 10.1111/j.1476-5381. 2011.01416.x. Search in Google Scholar

24. H. Toba, T. Mitani, T. Takahashi, N. Imai, R. Serizawa, J. Wang, M. Kobara and T. Nakata, Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type1 diabetes, Clin. Exp. Pharmacol. Physiol. 37 (2010) 1064-1070; DOI: 10.1111/j.1440-1681.2010.05436.x.10.1111/j.1440-1681.2010.05436.x20678154Search in Google Scholar

25. G. Nickenig and D. G. Harrison, The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis, Circulation 105 (2002) 393-396; DOI: 10.1161/hc0302.102618.10.1161/hc0302.10261811804998Search in Google Scholar

26. S. L. Belmonte, B. C. Blaxall, PKC-ing is believing: targeting protein kinase C in heart failure, Circ. Res. 109 (2011) 1320-1322; DOI: 10.1161/CIRCRESAHA.111.259358.10.1161/CIRCRESAHA.111.25935822158646Search in Google Scholar

27. A. L. Beck, M. E. Otto, L. B. D’Avila, F. M. Netto, M. K. Armendaris and A. C. Sposito, Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals, Atherosclerosis 222 (2012) 444-448; DOI: 10.1016/j.atherosclerosis. 2012.03.030.Search in Google Scholar

28. X. Zhou, D. Shang, T. Zhang, L. Li, T. Zhou and W. Lu, Modeling of angiotensin II-angiotensin-( 1 ) counterbalance in disease progression in spontaneously hypertensive rats treated with/ without perindopril, Pharmacol. Res. 66 (2012) 177-184; DOI: 10.1016/j.phrs.2012.04.001.10.1016/j.phrs.2012.04.00122513176Search in Google Scholar

29. M. J. Crespo, N. Cruz, P. I. Altieri and N. Escobales, Enalapril and losartan are more effective than carvedilol in preventing dilated cardiomyopathy in the Syrian cardiomyopathic hamster, J. Cardiovasc. Pharmacol. Ther. 13 (2008) 199-206; DOI: 10.1177/1074248408320006.10.1177/107424840832000618593848Search in Google Scholar

30. M. R. O’Grady, M. L. O’Sullivan, S. L. Minors and R. Horne, Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers, J. Vet. Intern. Med. 23 (2009) 977-983; DOI: 10.1111/j.1939-1676.2009.0346.x.10.1111/j.1939-1676.2009.0346.x19572914Search in Google Scholar

31. G. Pela, P. Pattoneri, M. Passera, G. Tirabassi, C. Reverberi, A. Montanari and T. Gherli, Long- -term effects of perindopril on left ventricular structure and function in patients with stable coronary artery disease: a conventional and Doppler tissue echocardiographic pilot study, J. Cardiovasc. Med. (Hagerstown) 10 (2009) 781-786; DOI: 10.2459/JCM.0b013e32832dbfe9. 10.2459/JCM.0b013e32832dbfe919525856Search in Google Scholar